[go: up one dir, main page]

DK1961767T3 - Diagnosis and treatment of cancers and other disorders - Google Patents

Diagnosis and treatment of cancers and other disorders

Info

Publication number
DK1961767T3
DK1961767T3 DK08156593.9T DK08156593T DK1961767T3 DK 1961767 T3 DK1961767 T3 DK 1961767T3 DK 08156593 T DK08156593 T DK 08156593T DK 1961767 T3 DK1961767 T3 DK 1961767T3
Authority
DK
Denmark
Prior art keywords
cancers
disorders
diagnosis
treatment
proline
Prior art date
Application number
DK08156593.9T
Other languages
Danish (da)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2579A external-priority patent/AUPR257901A0/en
Priority claimed from AUPR5891A external-priority patent/AUPR589101A0/en
Priority claimed from AUPR5890A external-priority patent/AUPR589001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Application granted granted Critical
Publication of DK1961767T3 publication Critical patent/DK1961767T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

There is provided an isolated P2X7 receptor, comprising an amino acid sequence having homology to the sequence shown in Figure 1, wherein the amino acid sequence of the isolated P2X7 receptor contains a proline corresponding to proline 210 shown in Figure 1, said proline being in a cis conformation.
DK08156593.9T 2001-01-17 2002-01-17 Diagnosis and treatment of cancers and other disorders DK1961767T3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPR2579A AUPR257901A0 (en) 2001-01-17 2001-01-17 Diagnosis and treatment of malignant lymphoma
AUPR025701 2001-01-17
AUPR5891A AUPR589101A0 (en) 2001-06-22 2001-06-22 Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors
AUPR5890A AUPR589001A0 (en) 2001-06-22 2001-06-22 An antibody cancer therapeutic
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
EP02715313A EP1360203B1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions

Publications (1)

Publication Number Publication Date
DK1961767T3 true DK1961767T3 (en) 2012-05-29

Family

ID=27507500

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08156593.9T DK1961767T3 (en) 2001-01-17 2002-01-17 Diagnosis and treatment of cancers and other disorders
DK02715313T DK1360203T3 (en) 2001-01-17 2002-01-17 Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancer disorders and other conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02715313T DK1360203T3 (en) 2001-01-17 2002-01-17 Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancer disorders and other conditions

Country Status (15)

Country Link
US (10) US7326415B2 (en)
EP (2) EP1360203B1 (en)
JP (2) JP4384852B2 (en)
CN (2) CN101555283B (en)
AT (2) ATE548383T1 (en)
AU (1) AU2003235005B2 (en)
CA (1) CA2434490C (en)
DE (1) DE60230482D1 (en)
DK (2) DK1961767T3 (en)
ES (2) ES2383712T3 (en)
HK (3) HK1070903A1 (en)
MY (1) MY158262A (en)
PT (1) PT1360203E (en)
TW (1) TWI319011B (en)
WO (1) WO2002057306A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
ES2383712T3 (en) 2001-01-17 2012-06-25 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
TWI329648B (en) * 2001-09-03 2010-09-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
NZ546711A (en) * 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
WO2007146061A2 (en) * 2006-06-09 2007-12-21 University Hospitals Of Cleveland Cell collection and disease screening
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
US8067550B2 (en) 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
JP5670192B2 (en) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド Novel P2X7 epitope
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
CA2729868C (en) 2008-07-04 2018-07-10 Biosceptre International Limited Anti- p2x7 peptides and epitopes
CN107011434B (en) * 2008-12-19 2021-02-19 埃博灵克斯股份有限公司 Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
WO2011020155A1 (en) 2009-08-20 2011-02-24 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
CA2784345C (en) 2009-12-24 2018-11-13 Julian Alexander Barden Antibodies to non-functional oligomeric p2x7 receptors
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
JP6305920B2 (en) 2011-07-01 2018-04-04 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド Combination therapy
CN114891116A (en) 2015-09-11 2022-08-12 生物权威（英国）有限公司 Chimeric antigen receptor and uses thereof
EP3528789A4 (en) * 2016-10-21 2020-06-24 Biosceptre UK Limited Cytotoxic particles
BR122023024273A2 (en) 2018-02-27 2024-02-20 Incyte Corporation IMIDAZOPIRIMIDINE AND TRIAZOLOPYRIMIDIINE COMPOUNDS, THEIR USES, METHOD FOR INHIBITING AN ADENOSINE RECEPTOR ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF
MX2020012376A (en) 2018-05-18 2021-03-09 Incyte Corp Fused pyrimidine derivatives as a2a / a2b inhibitors.
JP7490631B2 (en) 2018-07-05 2024-05-27 インサイト・コーポレイション Fused pyrazine derivatives as A2A/A2B inhibitors
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
CN110054691B (en) * 2019-05-09 2021-09-07 潍坊医学院 A hybridoma cell line of anti-human P2RX7 monoclonal antibody
MX2021015593A (en) * 2019-07-26 2022-04-11 Biosceptre Aust Pty Ltd P2x7 receptor targeted therapy.
MX2022007573A (en) 2020-01-03 2022-09-23 Incyte Corp Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy.
AR120936A1 (en) 2020-01-03 2022-03-30 Incyte Corp ANTI-CD73 ANTIBODIES AND THEIR USES
CA3207066A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
MX2023011807A (en) * 2021-04-08 2024-01-05 Biosceptre Aust Pty Ltd METHODS TO CONTROL THE ACTIVITY OF IMMUNE CELLS.
AU2023343787A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
WO2024055077A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
WO2024055075A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1141314A (en) * 1914-12-19 1915-06-01 Eugene W Caldwell Photographic developing apparatus.
US2191508A (en) * 1939-02-06 1940-02-27 Stuart Robert Photographic film carrier and development receptacle
US3010460A (en) * 1958-07-03 1961-11-28 Geo B Hart Inc Apparatus for wetting absorbent bodies for moistening and supporting plant parts
US3077155A (en) * 1960-08-08 1963-02-12 Pako Corp Device for treating photographic sheet material
US3121438A (en) * 1961-01-16 1964-02-18 Union Carbide Corp Open head container and cover therefor
US3952756A (en) * 1974-06-14 1976-04-27 Purex Corporation Semi automatic parts cleaning machine
US4302273A (en) * 1980-06-04 1981-11-24 Rca Corporation Etching tank in which the solution circulates by convection
US4305413A (en) * 1980-07-25 1981-12-15 Ecology, Inc. Cleaning apparatus
US4550579A (en) * 1984-04-13 1985-11-05 Frank Clifford G Apparatus for the dyeing of shaped articles
US5104727A (en) * 1989-06-16 1992-04-14 W. L. Gore & Associates, Inc. Air bag laminates
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH0756015A (en) * 1993-08-18 1995-03-03 Sony Corp Production of color filter
WO1995033048A2 (en) 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
US5660640A (en) * 1995-06-16 1997-08-26 Joray Corporation Method of removing sputter deposition from components of vacuum deposition equipment
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (en) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Human P2x4 receptor splice-variant
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (en) 1997-03-26 2007-02-21 大塚製薬株式会社 Human gene
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US5851307A (en) * 1997-04-28 1998-12-22 Advanced Micro Devices, Inc. Method for in-situ cleaning of polysilicon-coated quartz furnaces
US5849091A (en) * 1997-06-02 1998-12-15 Micron Technology, Inc. Megasonic cleaning methods and apparatus
US5906216A (en) * 1997-10-10 1999-05-25 Barlet; Bruce N. Denture cleaning device
WO1999062941A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (en) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Procedure for early diagnosis of carcinomas
US6055694A (en) * 1998-11-30 2000-05-02 Tsk America, Inc. Wafer scrubbing machine
WO2000050458A1 (en) 1999-02-26 2000-08-31 Smithkline Beecham Corporation Cloning of a p2y-like 7tm receptor (axor17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (en) 1999-06-28 2001-01-02 Univ Delft Tech A process for the preparation of protein agglomerates, protein agglomerates, a foodstuff and a pharmaceutical preparation containing them and an apparatus for the preparation of protein agglomerates.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
ES2383712T3 (en) 2001-01-17 2012-06-25 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
TWI329648B (en) 2001-09-03 2010-09-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
PL1469072T3 (en) 2003-04-17 2008-03-31 Affectis Pharmaceuticals Ag Means and methods for diagnosing and treating affective disorders
US20090215727A1 (en) 2005-05-05 2009-08-27 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
US8067550B2 (en) 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
JP5670192B2 (en) 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド Novel P2X7 epitope
CA2729868C (en) 2008-07-04 2018-07-10 Biosceptre International Limited Anti- p2x7 peptides and epitopes
WO2011020155A1 (en) 2009-08-20 2011-02-24 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
CA2784345C (en) 2009-12-24 2018-11-13 Julian Alexander Barden Antibodies to non-functional oligomeric p2x7 receptors
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
JP6305920B2 (en) 2011-07-01 2018-04-04 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド Combination therapy

Also Published As

Publication number Publication date
ATE418565T1 (en) 2009-01-15
AU2003235005A1 (en) 2003-09-11
PT1360203E (en) 2009-04-03
EP1360203A4 (en) 2005-06-22
EP1961767A3 (en) 2008-10-29
CN101555283A (en) 2009-10-14
US20040142342A1 (en) 2004-07-22
JP2009235074A (en) 2009-10-15
HK1138013A1 (en) 2010-08-13
WO2002057306A1 (en) 2002-07-25
EP1360203B1 (en) 2008-12-24
AU2003235005B2 (en) 2007-09-20
AU2003235005A8 (en) 2003-09-11
EP1360203A1 (en) 2003-11-12
HK1123311A1 (en) 2009-06-12
CA2434490A1 (en) 2002-07-25
US20090192293A1 (en) 2009-07-30
US7888473B2 (en) 2011-02-15
EP1961767B1 (en) 2012-03-07
ES2383712T3 (en) 2012-06-25
CN101555283B (en) 2012-03-21
CA2434490C (en) 2014-06-03
US10450380B2 (en) 2019-10-22
US20120059151A1 (en) 2012-03-08
US8399617B2 (en) 2013-03-19
US7531171B2 (en) 2009-05-12
JP4384852B2 (en) 2009-12-16
ATE548383T1 (en) 2012-03-15
US20080131438A1 (en) 2008-06-05
US20150274839A1 (en) 2015-10-01
US20110092674A1 (en) 2011-04-21
US20200071419A1 (en) 2020-03-05
EP1961767A2 (en) 2008-08-27
TWI319011B (en) 2010-01-01
HK1070903A1 (en) 2005-06-30
US8080635B2 (en) 2011-12-20
US7326415B2 (en) 2008-02-05
US20140323693A1 (en) 2014-10-30
MY158262A (en) 2016-09-30
JP2004528286A (en) 2004-09-16
ES2320421T3 (en) 2009-05-22
US9663584B2 (en) 2017-05-30
CN1541222A (en) 2004-10-27
JP4457169B2 (en) 2010-04-28
DK1360203T3 (en) 2009-04-20
US8709425B2 (en) 2014-04-29
US20130245226A1 (en) 2013-09-19
CN100497385C (en) 2009-06-10
DE60230482D1 (en) 2009-02-05
US20170327592A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
DK1961767T3 (en) Diagnosis and treatment of cancers and other disorders
TR200401871T4 (en) Preparation of modified octanoyl amides (octanoyl amides)
EA200300464A1 (en) HUMAN LIFE
DK2308855T3 (en) 2,4-Diamino
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
DE60137876D1 (en) Glucagon-like peptide-1 analogs
EP1385421A4 (en) IDENTIFICATION, DIAGNOSIS AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITY, TUMORS AND BRAIN AND BACK MARK INJURIES BY MICROELECTRODES WITH MICROVOLTAMMETRY
BR0008056A (en) Substituted fused pyrrolocarbazoles and cyclic isoindolones
HUP0101719A2 (en) Improved immunodiagnostic assays using reducing agents
EP1357909A4 (en) Il-8 receptor antagonists
DE60211810D1 (en) PYROLYSEROHR AND THIS USE PYROLYSIS PROCESS
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
ATE417856T1 (en) MOTILIDE COMPOUNDS
ATE499079T1 (en) COMPONENT ARRANGEMENT AND COMPONENT FOR A PROSTHESIS
DE60112671D1 (en) Curved, elastic tooth regulating ring
EA200400392A1 (en) BINDING KASPAZU-8 PROTEIN, ITS OBTAINING AND APPLICATION
DE60036469D1 (en) 17867, A HUMAN AMINO PEPTIDASE
ATE324212T1 (en) SPACER ELEMENT FOR A COLLET AND COLLET
BR0212295A (en) Test
DE60042056D1 (en) Human carnosinase 2
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
GB2368524B (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
DK1395289T3 (en) Treatment of neuropathic pain with an N-methyl-D-aspartate (NMDA) receptor antagonist
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
DE69104363D1 (en) VINYLSULFONYL PRISTINAMYCINE AND THEIR PRODUCTION.